RU2017140779A - Композиции для лечения рака - Google Patents

Композиции для лечения рака Download PDF

Info

Publication number
RU2017140779A
RU2017140779A RU2017140779A RU2017140779A RU2017140779A RU 2017140779 A RU2017140779 A RU 2017140779A RU 2017140779 A RU2017140779 A RU 2017140779A RU 2017140779 A RU2017140779 A RU 2017140779A RU 2017140779 A RU2017140779 A RU 2017140779A
Authority
RU
Russia
Prior art keywords
amd3100
compositions
standard dose
cancer treatment
cumulative standard
Prior art date
Application number
RU2017140779A
Other languages
English (en)
Inventor
Патрик РИВЗ
Марк К. ПОЗНАНСКИЙ
Original Assignee
Дзе Дженерал Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Дженерал Хоспитал Корпорейшн filed Critical Дзе Дженерал Хоспитал Корпорейшн
Publication of RU2017140779A publication Critical patent/RU2017140779A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

1. Фармацевтический продукт, содержащий совокупную стандартную дозу AMD3100, составляющую примерно 50-350 мг/кг, вводимый на протяжении периода времени от 7 до 14 дней.
2. Набор компонентов, включающий первый контейнер, содержащий совокупную стандартную дозу AMD3100, составляющую примерно 50-350 мг/кг, и второй контейнер, содержащий противораковое терапевтическое средство.
3. Набор компонентов по п. 2, дополнительно включающий читаемый носитель информации с указаниями о необходимости завершения введения совокупной стандартной дозы AMD3100 до начала введения противоракового средства.
RU2017140779A 2015-04-24 2016-04-25 Композиции для лечения рака RU2017140779A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152815P 2015-04-24 2015-04-24
US62/152,815 2015-04-24
US201562152824P 2015-04-25 2015-04-25
US62/152,824 2015-04-25
PCT/US2016/029258 WO2016172730A1 (en) 2015-04-24 2016-04-25 Compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
RU2017140779A true RU2017140779A (ru) 2019-05-24

Family

ID=57144335

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017140779A RU2017140779A (ru) 2015-04-24 2016-04-25 Композиции для лечения рака

Country Status (11)

Country Link
US (1) US20180117005A1 (ru)
EP (1) EP3285763A4 (ru)
JP (1) JP2018514586A (ru)
KR (1) KR20180035733A (ru)
CN (1) CN108024991A (ru)
AU (1) AU2016253153A1 (ru)
CA (1) CA2983762A1 (ru)
IL (1) IL255167A0 (ru)
MX (1) MX2017013669A (ru)
RU (1) RU2017140779A (ru)
WO (1) WO2016172730A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348590A (zh) * 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 用于治疗癌症的具有抗趋除特性的组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
WO2007048074A1 (en) * 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
US9198597B2 (en) * 2008-05-22 2015-12-01 Christopher Duma Leading-edge cancer treatment
US9155723B2 (en) * 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
CA2983762A1 (en) 2016-10-27
WO2016172730A1 (en) 2016-10-27
IL255167A0 (en) 2017-12-31
CN108024991A (zh) 2018-05-11
MX2017013669A (es) 2018-07-06
EP3285763A1 (en) 2018-02-28
JP2018514586A (ja) 2018-06-07
KR20180035733A (ko) 2018-04-06
EP3285763A4 (en) 2018-12-05
US20180117005A1 (en) 2018-05-03
AU2016253153A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
MX2017010280A (es) Complejos de acetato de abiraterona, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
PH12017501769A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
RU2017140779A (ru) Композиции для лечения рака
MY188302A (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом
MX2019003943A (es) Farmaco eficaz para un metodo linfogeno de administracion de farmaco.
EA202090842A1 (ru) Таблетки деферипрона с отсроченным высвобождением и способы их применения
EA201650133A1 (ru) Твердые лекарственные формы тадалафила
EA201892709A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA91282U (ru) Фармацевтический продукт, обладающий выраженным антигестагенным действием
TH183323B (th) สูตรที่ให้ทางปากของดีฟีราซิรอกซ์ (deferasirox)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20201124